Alvotech
ALVO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001898416
No open-market purchases or sales by Alvotech insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $157.4M in total; Oaktree Capital is the only superinvestor holding it.
Other share classesALVOW
Q3 2023 vs. Q2 2023
How the institutions holding Alvotech changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 17 | 19 | +2 |
| Shares | 17.6M | 17.8M | +216.3K (+1.2%) |
| Value | $133.5M | $159.7M | +$26.2M (+19.6%) |
New holders (4)
Institutions that held Alvotech at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Vanguard Group Inc | 2,881,396 | $26.3M | 0.00% |
| UBS Group AG | 78 | $711 | 0.00% |
| Qube Research & Technologies Ltd | 16 | $146 | 0.00% |
| Morgan Stanley | 1 | $9 | 0.00% |
Sold out (2)
Institutions that held Alvotech at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Farallon Capital Management, L.L.C. | 437,110 | $3.38M |
| HRT Financial LP | 16,855 | $130.0K |